Menu
Recruiting NCT07053605

Clinical Study on Laparoscopic Resection of Splenic Artery Aneurysm With Preservation of Spleen

No phase Interventional Splenic Artery Aneurysm Immune Function Hemodynamics

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: laparoscopic resection of splenic artery aneurysm with preservation of spleen.
Who it may be relevant to
Registry conditions: Splenic Artery Aneurysm, Immune Function, Hemodynamics. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

In this study, researchers examined the changes in related indicators such as immune function, splenic vein,proper hepatic artery, and portal venous hemodynamics following laparoscopic resection of a splenic artery aneurysm. We determined the changes in these patient-related indicators after surgical treatment and whether these changes could improve patient outcomes.

Detailed description

Patients with Splenic Artery Aneurysm were recruited in accordance with the research inclusion criteria, and their general demographic information was collected. After thorough preoperative preparation, the same surgical team performed laparoscopic resection of the splenic artery aneurysm. Postoperatively,the same nursing team provided standardized care. Subsequently, patients received a standardized postoperative treatment protocol, which included pharmacotherapy, additional therapeutic interventions, and follow-up visits. During the treatment period, routine blood tests,liver function tests, coagulation function,immune function, as well as the hemodynamics of the portal vein, proper hepatic artery, and splenic vein were monitored preoperatively and at 7 days, 1 month, 3 months, 6 months, and 12 months postoperatively.

Interventions

  • Procedure laparoscopic resection of splenic artery aneurysm with preservation of spleen
    The laparoscopic resection of splenic artery aneurysm with preservation of spleen is performed by the same surgical team.

Primary outcome measures

  • The immune function at 7 days after surgery [Time frame: 7 days]
  • The immune function at 1 month after surgery [Time frame: 1 month]
  • The immune function at 3 months after surgery [Time frame: 3 months]
  • The immune function at 6 months after surgery [Time frame: 6 months]
  • The immune function at 12months after surgery [Time frame: 12months]
  • Routine blood tests (Erythrocyte Count; Hemoglobins; Red Cell Distribution Width; White Blood Cell Count; Neutrophils; Lymphocytes; Monocytes; Eosinophils; Basophils; Platelet Count; Mean Platelet Volume; Blood Platelet) at 1 month postoperatively. [Time frame: 1 month]
  • Routine blood tests (Erythrocyte Count; Hemoglobins; Red Cell Distribution Width; White Blood Cell Count; Neutrophils; Lymphocytes; Monocytes; Eosinophils; Basophils; Platelet Count; Mean Platelet Volume; Blood Platelet) at 3 months postoperatively. [Time frame: 3 months]
  • Routine blood tests (Erythrocyte Count; Hemoglobins; Red Cell Distribution Width; White Blood Cell Count; Neutrophils; Lymphocytes; Monocytes; Eosinophils; Basophils; Platelet Count; Mean Platelet Volume; Blood Platelet) at 6 months postoperatively. [Time frame: 6 months]
  • Routine blood tests (Erythrocyte Count; Hemoglobins; Red Cell Distribution Width; White Blood Cell Count; Neutrophils; Lymphocytes; Monocytes; Eosinophils; Basophils; Platelet Count; Mean Platelet Volume; Blood Platelet) at 12 months postoperatively. [Time frame: 12 months]
  • Hemodynamics (Vascular Diameter; Blood Flow Velocity) of the splenic vein,proper hepatic artery,and portal vein at 1 month postoperatively. [Time frame: 1 month]

Eligibility criteria

Inclusion criteria

  • Asymptomatic splenic artery aneurysms with a diameter>2 cm,ruptured splenic artery aneurysms,and splenic artery aneurysms with a diameter increase>0.5 cm/year.

Aneurysm located in the main trunk of the splenic artery. Informed consent to participate in the study.

Exclusion criteria

  • Patients with malignancies Hepatic cirrhosis with portal hypertension peptic ulcer disease Recent peptic ulcer disease History of Hemorrhagic stroke Pregnancy hematological diseases Uncontrolled Hypertension Human immunodeficiency virus (HIV) infection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Clinical Medical College, Yangzhou University — Yangzhou

Identifiers

NCT: NCT07053605 · YZUC-013

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗